Don’t expect much from your microdose. Psychedelic-assisted therapy is likely where the magic lies. Yarygin/Getty Images
Microdosing is popular for obvious reasons, but it likely isn’t enough
According to a new study published in Translational Psychiatry, “microdosing” probably gets more credit than it deserves.
The practice became a life hack for Silicon Valley CEOs and scatterbrained college students alike in the 2010s. But it’s only increased in popularity as the edibles market has taken off, and psychedelics (e.g., ketamine, psilocybin, MDMA, DMT) have become more readily available and coupled with psychotherapy.
But while such psychoactive drugs have finally started earning credit for their positive potential in the realm of mental health — the FDA is expected to officially approve psilocybin and MDMA therapies within the next two years — it’s increasingly clear that in order to achieve quantifiable mental health benefits, a microdose probably isn’t going to cut it. A proper “trip” is more like it.
For the recent double-blind study, scientists gave 34 volunteers two doses of a psilocybin one week, and two doses of a placebo the next. Fascinatingly, as reported by PsyPost, researchers found no “positive impact of psilocybin on subjects’ creativity, cognition, or self-reported mental well-being” over the placebo.
What does that mean? Well, to be clear, EEG readings (a measure of brain activity), did display a difference while on psilocybin as opposed to the placebo. But at such low levels of dosage, there wasn’t a noteworthy gap to report. And among the few volunteers who reported in their questionnaire that they felt more creative or perceptive, they were also the only ones who’d correctly guessed when they were taking psilocybin.
To Read The Rest Of This Article By Tanner Garrity on Inside Hook
Published: September 15, 2022
Founder & Interim Editor of L.A. Cannabis News